NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

Go back to NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
(NASDAQ: NRSN) Delayed: 2.37 +0.04 (1.72%)
Previous Close $2.33    52 Week High $ 
Open $2.30    52 Week Low $ 
Day High $2.60    P/E N/A 
Day Low $2.28    EPS $ 
Volume 22,275